2655656-99-6

KT-413 (example I-3) is an orally active PROTAC-class IRAK degrader[1]. KT-413 consists of a target protein ligand (red part) PROTAC IRAK4 ligand-5 (HY-168311), an E3 ubiquitin ligase ligand (blue part) Thalidomide-4-Br (HY-W039116), and a PROTAC linker (black part) 2-(2-Azaspiro[3.3]heptan-6-yl)ethanamine (HY-168313). E3 ubiquitin ligase and linker can form Thalidomide-NH-C2-2-azaspiro[3.3]heptane (HY-168312). The active control for the target protein ligand is RSL3-4-Me (HY-169375).

[1] Weiss Matthew M. Preparation of benzothiazole derivatives as IRAK degraders and uses thereof. World Intellectual Property Organization, WO2021127190 A1. 2021-06-24.
[2] Zeng S, et al. Current advances and development strategies of orally bioavailable PROTACs. Eur J Med Chem. 2023 Dec 5;261:115793. DOI:10.1016/j.ejmech.2023.115793